Clinical Trial Update: Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating memantine 10 mg twice daily for frontal and temporal subtypes of frontotemporal dementia has completed with posted results in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontal Lobe Dementia
• Frontotemporal Dementia
• Semantic Dementia

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Frontal Lobe Dementia, Frontotemporal Lobe Dementia | Phase 4 | Status: COMPLETED | Results posted: 2014-02-05